This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Canadian Blood Services. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Ed Pryzdial: Innovator in Fibrinolytic Therapeutics
Introduction
Ed Pryzdial is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of biochemistry, particularly in the development of therapeutic applications related to coagulation proteins. His innovative work has the potential to impact medical treatments for thrombolytic and fibrinolytic conditions.
Latest Patents
Ed Pryzdial holds a patent for "C-terminally tethered amino acids and their fibrinolytic therapeutic uses." This patent provides a C-terminal tethered amino acid designed to modulate the thrombolytic, fibrinolytic, and anticoagulant properties of coagulation proteins. The disclosure also includes a coagulation protein with a modified catalytic site, either at the histidine or serine residue, utilizing the C-terminal tethered amino acid. The therapeutic applications of these modified coagulation proteins are promising for advancing medical treatments.
Career Highlights
Ed Pryzdial is associated with Canadian Blood Services, where he applies his expertise in biochemistry to enhance therapeutic solutions. His work focuses on improving the efficacy of treatments related to blood coagulation and related disorders.
Conclusion
Ed Pryzdial's contributions to the field of fibrinolytic therapeutics exemplify the impact of innovative thinking in medicine. His patent and ongoing work at Canadian Blood Services highlight the importance of research in developing effective treatments for coagulation-related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile